First to market. The ultimate pain reliever for a generic pharmaceutical company.

submitted by: Clare Hovan

In the world of generic pharmaceuticals, there’s a simple saying: He who reaches the market first gets the biggest return. Little wonder Apotex wanted to decrease their overall cycle time from inception through to product launch. View the video clip to find out how Apotex hit their time line. Or view the entire video at www.waters.com/desai

Conus Peptides: Part 3: Conus Peptide Genes a "Drug Development Program" (25.36)

submitted by: scivee-team
Although snails are not the first animals that come to mind when venoms are mentioned, there are in fact a large number (~10,000 species) of different venomous predatory snails. The most intensively studied of these are the cone snails (Conus), which have a large number of peptide neurotoxins present in their venoms. Some cone snail venoms are lethal to man; one species causes a 70% fatality rate. How these venoms have been used to understand the nervous system, and how the characterization...

CLC Bio

submitted by: dougramsey
We provide integrated bioinformatics solutions including sequence analysis software, high-performance computing, consulting, and education to pharmaceutical and biotechnology companies, as well as hospitals and universities all over the world. We hereby facilitate research into genetically determined diseases, drug development, molecular diagnostics, agricultural research, and more. Our bioinformatics solutions are designed and built to leverage the latest technological innovations,...

Illumina

submitted by: dougramsey
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As...

Alzheimer's Disease

submitted by: alex01
Z. Khachaturian, PhD. - New approaches to the therapy of Alzheimer’s disease (AD) are discussed in video interviews of this series. According to Z. Khachaturian (Potomac, MD) substantial progress has been made during the last 10 years in our understanding of pathogenesis of Alzheimer’s disease as well as in the discovery of biomarkers and therapeutic approaches. In addition to cholinergic drugs, inhibitors of plaque formation have been discovered, but the currently available...

Malaria presented by Joseph DeRisi, June 2006 - Part 1: Malaria: Background & Overview (21:19)

submitted by: video_collector

This brief set of three lectures gives a very general overview of malaria, the disease and Plasmodium falciparum, the causative agent of the most deadly form. Basic research as well as drug development efforts will also be covered in parts two and three of this series. For further information see: http://www.ascb.org/ibioseminars/DeRisi/DeRisi1.cfm